Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

Company Overview

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $64.97 to $64.97
• 50-Day Range: $64.37 to $64.97
• 52-Week Range: $8.33 to $65.00
• Volume: 2 shs
• Average Volume: 1.92 million shs
• Market Capitalization: $4.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.63
• Consensus Rating: Hold

Alpine Immune Sciences Stock Analysis - MarketRank™

Alpine Immune Sciences scored higher than 6% of companies evaluated by MarketBeat, and ranked 938th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Alpine Immune Sciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alpine Immune Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.74) to ($1.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpine Immune Sciences is -101.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpine Immune Sciences is -101.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpine Immune Sciences has a P/B Ratio of 13.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ALPN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpine Immune Sciences does not currently pay a dividend.

Dividend Growth

Alpine Immune Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ALPN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ALPN on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpine Immune Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALPN Stock Analysis - Frequently Asked Questions

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of $0.01 by $0.56. The biotechnology company earned $8.52 million during the quarter, compared to analyst estimates of $22.30 million. Alpine Immune Sciences had a negative net margin of 65.17% and a negative trailing twelve-month return on equity of 14.86%.

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALPN
• CUSIP: N/A
• CIK: 1626199
• Web: www.alpineimmunesciences.com
• Phone: (206) 788-4545
• Fax: 303-440-8399
• Employees: 142
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.63
• High Stock Price Target: $65.00
• Low Stock Price Target: $44.00
• Potential Upside/Downside: -12.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,180,000.00
• Net Margins: -65.17%
• Pretax Margin: -64.99%
• Return on Equity: -14.86%
• Return on Assets: -11.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.56
• Quick Ratio: 9.56

Sales & Book Value

• Annual Sales: $56.52 million
• Price / Sales: 78.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.85 per share
• Price / Book: 13.40

Miscellaneous

• Outstanding Shares: 68,598,000
• Free Float: 39,581,000
• Market Cap: $4.46 billion
• Optionable: Optionable
• Beta: 0.97